Navigation Links
PDL BioPharma Announces Fourth Quarter and Full Year 2011 Financial Results
Date:2/23/2012

more information, please visit www.pdl.com.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.

Forward-looking StatementsThis press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from those, express or implied, in these forward-looking statements. Important factors that could impair the value of the Company's royalty assets, restrict or impede the ability of the Company to invest in new royalty bearing assets and limit the Company's ability to pay dividends are disclosed in the risk factors contained in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission and updated by subsequent Quarterly Reports on Form 10-Q. All forward-looking statements are expressly qualified in their entirety by such factors. We do not undertake any duty to update any forward-looking statement except as required by law.PDL BIOPHARMA, INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS DATA(Unaudited)(In thousands, except per share amounts)Three Months EndedYear EndedDecember 31,December 31,2011201020112010RevenuesRoyalties$ 72,808$  74,629$ 351,641$ 343,475License and other-1,50010,4001,500Total revenues72,80876,129362,041344,975Operating ExpensesGeneral and administrative expenses4,82212,05618,33841,396Legal Settlement-92,500-92,500Total operating expenses4,822104,55618,338133,896Operating income (loss)67,986(28,427)343,703211,079Non-operating expense, netGain (loss) on retirement or conversion of convertible notes-1,033(766)(17,648)Interest and other income, net130131593468Interest expense(8,161)(9,514)(36,102)(43,529)Total non-operating expense, net(8,031)(8,350)(36,275)(60,709)Income befor
'/>"/>

SOURCE PDL BioPharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. Canopus Biopharma and Leading Chinese Researcher Team Up to Treat Avian Influenza, to Prevent Possible Pandemic
3. Ondine Biopharma Announces Second Quarter 2008 Financial Results
4. ARCA biopharma Appoints William R. Hiatt as Director of Clinical and Regulatory Strategy
5. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
6. Leading Biopharmas Will Deliver Case Studies on Achieving Productivity Excellence through Engagement, Technology, Other Tools
7. Therapure Biopharma Inc. opens for business with first client contracts
8. Top Biopharma Company Adopts BioFortis Translational Research Software for Centralized Management and Mining of Clinical Biomarker Data
9. China Biopharma Effects 1 for 100 Reverse Stock Split
10. Cyntellect Launches CellXpress(TM) System to Boost Productivity of Biopharmaceutical Process Development
11. FDA Accepts New Drug Application for Bucindolol, A Genetically-Targeted Treatment for Heart Failure From ARCA biopharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Shimadzu Scientific Instruments introduces its Open Solution QuantAnalytics(TM) ... management and clinical markets. The software increases the speed ... users to highlight and review results that are of ... to filter results by group or based on a ... need to sift through analytes of no interest. In ...
(Date:10/22/2014)... UAE (PRWEB) October 22, 2014 Grace ... science and healthcare projects, announces the addition of ... DCH to its advisory team. Dr. Siddiqui will provide ... , A graduate of University College Medical ... subsequently degreed in medicine in 2001. With further certification ...
(Date:10/22/2014)... , Oct. 22, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" ... announced next steps for its Oral Amphotericin B ... its in vitro work involving samples ... now plans to complete pre clinical studies and ... Phase 1A clinical trial, utilizing approximately $700,000 of ...
(Date:10/20/2014)... The report “Pharmacy Automation Systems Market ... Labeling Systems, Table-top Counters) by End-user (Inpatient Pharmacy ... Trends to 2019” analyzes and studies the major ... Europe, Asia-Pacific, and the Rest of the World ... figures spread through 300 pages and in-depth TOC ...
Breaking Biology Technology:Shimadzu Releases QuantAnalytics Open Access LCMS Software Package for Clinical Applications 2Dr. Yousef Siddiqui joins the Grace Century Advisory Team 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4
... ... Intellectual Property, FULLERTON, Calif., Nov. 28 Beckman Coulter,Inc. ... and,automate complex biomedical testing announced today that it has entered,into an ... spin out of Lumigen, Inc., effected prior to Beckman,Coulter,s acquisition of ...
... Cambridge Research &,Instrumentation (CRi) announced today that ... of allowance for their patent application number,10/669,101, for ... patent covers the use of multispectral imaging combined,with ... of,fluorophores in a living mammal. The unmixing of ...
... 1-41 has significant ... and anti-amnesic benefits, GENEVA, Nov. 28 /PRNewswire-FirstCall/ - ... announce promising developments with,ANAVEX 1-41, the company,s lead drug ... 1-41 prevented oxidative stress,which damages and destroys cells and ...
Cached Biology Technology:Beckman Coulter to Acquire Exclusive Rights to Break-Through Technologies 2US Patent and Trademark Office Allows CRi's Patent Application for Spectral Imaging of Deep Tissue 2Anavex advances drug candidate for treatment of Alzheimer's disease 2Anavex advances drug candidate for treatment of Alzheimer's disease 3Anavex advances drug candidate for treatment of Alzheimer's disease 4Anavex advances drug candidate for treatment of Alzheimer's disease 5
(Date:10/16/2014)... , October 16, 2014 NXT-ID, Inc. ... the "Company"), a biometric authentication company focused on the ... leading edge technologies including Wocket™, the Smart Wallet, at ... Conferenece. FiRe is a leading global conference on the ... Hosted by Mark Anderson , founder and publisher ...
(Date:10/15/2014)... to an unexpected extent. The outbreak does not follow ... shows a new disease dynamic in regions, where it ... German National Academy of Sciences Leopoldina, acatech – the ... of the German Academies of Sciences and Humanities have ... In the statement the academies call for the following ...
(Date:10/14/2014)... prostate cancer tumors scavenge and hoard copper that is ... may be a fatal weakness. , Researchers at ... cancer cells by delivering a trove of copper along ... brimming with the mineral, leaving non-cancer cells healthy. , ... available for other uses, could soon be tested in ...
Breaking Biology News(10 mins):NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5Prostate cancer's penchant for copper may be a fatal flaw 2
... characterise their Zap-It! product, which uses the tiny electric ... itching caused by insect bites - such as those from ... that is based around a similar piezoelectric mechanism to that ... a medical device, currently available to buy in high street ...
... Molecular biologist Ichiro Matsumoto, Ph.D., of the Monell Center, ... Young Investigators in Gustation, awarded annually by the Association ... who is an emerging leader in the field of ... the understanding of the organization, relationships and connectivity of ...
... of the potentially deadly antibiotic-resistant bacterium known as MRSA ... a new study involving two Northern Arizona University researchers., ... for Microbial Genetics and Genomics, and Lance Price, NAU ... Microbiology and Environmental Health at the Translational Genomics Research ...
Cached Biology News:Zapping mosquito bites 2Evolution of staph 'superbug' traced between humans and food animals 2
...
...
Immunogen: Peptide corresponding to amino acid residues from the N-terminal region of human thyroid hormone receptor, alpha1/alpha2-isotype. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Antibodies were affinity purified using epitopes specific to QKI immobilized on solid support....
Biology Products: